Brief: Actinium Pharmaceuticals Reports New Analyses From Positive Phase 3 Trial of Iomab-B
26/02/2024 12:38
Feb 26 (Reuters) - Actinium Pharmaceuticals Inc
ATNM.A :
* ACTINIUM PHARMACEUTICALS INC - IOMAB-B HAS ALSO
DEMONSTRATED
IMPROVED OUTCOMES IN PATIENTS WITH HIGH-RISK FEATURES INCLUDING
A TP53 MUTATION
* ACTINIUM - IOMAB-B MARKEDLY INCREASES LONG TERM SURVIVAL
IN
PATIENTS 65 YEARS OR OLDER WITH ACTIVE RELAPSED OR REFRACTORY
AML IN PHASE 3 SIERRA TRIAL
Source text for Eikon: ID:nPnc6vTkWa
Further company coverage: ATNM.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Actinium Pharmaceuticals
See all newsBrief: Actinium Pharmaceuticals - Receives Two Canadian Patent Allowances For Actimab-A And Iomab-Act Programs
Brief: ctinium’s Atnm-400 Shows Strong Efficacy in TNBC, Beats Therapy Resistance at SABCS
Brief: Actinium Pharmaceuticals Says ATNM-400 Shows Superior Efficacy To Xtandi In Prostate Cancer
Brief: Actinium Pharmaceuticals Announces ATNM-400 A Novel Non-PSMA Targeting First In Class Prostate Cancer Radiotherapy Leveraging Actinium-225
Brief: Actinium Pharmaceuticals Announces Supply Agreement With Eckert & Ziegler For AC-225 Radioisotope To Support Comprehensive Development Activities